期刊
ONCOTARGET
卷 7, 期 37, 页码 60087-60100出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11065
关键词
RAD51; kinome; triple negative breast cancer; p38MAP Kinase; targeted therapy
资金
- National Breast Cancer Foundation Australia [PF-13-12, ECF-11-09, NC-13-26]
- Cancer Council Queensland [APP1045620]
- National Health and Medical Research Council [APP106851]
- ARC Future Fellowship [FT130101417]
- National Breast Cancer Foundation [PF-13-12, NC-13-26] Funding Source: researchfish
- Australian Research Council [FT130101417] Funding Source: Australian Research Council
The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mechanisms including; increased expression of the target gene PARP1, increased expression or reversion mutation of BRCA1, or up-regulation of the compensatory homologous recombination protein RAD51. Indeed, RAD51 has been demonstrated to be an alternative synthetic lethal target in BRCA1-mutated cancers. To overcome selective pressure on DNA repair pathways, we examined new potential targets within TNBC that demonstrate synthetic lethality in association with RAD51 depletion. We confirmed complementary targets of PARP1/2 and DNA-PK as well as a new synthetic lethality combination with p38. p38 is considered a relevant target in breast cancer, as it has been implicated in resistance to chemotherapy, including tamoxifen. We show that the combination of targeting RAD51 and p38 inhibits cell proliferation both in vitro and in vivo, which was further enhanced by targeting of PARP1. Analysis of the molecular mechanisms revealed that depletion of RAD51 increased ERK1/2 and p38 signaling. Our results highlight a potential compensatory mechanism via p38 that limits DNA targeted therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据